Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

iwNHL 2015 | iwNHL 2015 roundtable: Immune checkpoint blockade for non-Hodgkin lymphoma

At the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2015 meeting, John Gribben, MD, DSc, FRCPath, FRCP FMedSci, of Barts and The London School of Medicine and Dentistry, London, UK, chairs a discussion with Anas Younes, MD, of Memorial Sloan Kettering Cancer Center, New York, NY, Stephen M. Ansell, MD, PhD, of Mayo Clinic, Rochester, MN, and Nathan H. Fowler, MD, of The University of Texas MD Anderson Cancer Center, Houston, TX, on emerging immune targets, such as the interaction between programmed death ligand-1 (PD-L1) and programmed cell death-1 (PD-1), that are demonstrating clinical responses with the use of immune checkpoint inhibitors in patients with non-Hodgkin lymphoma.